In a recent study at the University of Liverpool, researchers found that in adults with obesity or overweight, weekly treatment with the glucagon-like peptide 1 (GLP1) receptor agonist semaglutide leads to lower excess body fat and increased lean body mass.
The findings suggest that semaglutide, an FDA-approved diabetes drug, can help with bodyweight loss and improvement of body composition.
It has the potential to reduce the risk of heart disease, diabetes and stroke in people with overweight or obesity.
The study is published in The New England Journal of Medicine. One author is John Wilding, D.M., F.R.C.P.
Excess fat in the abdominal area, particularly fat in and around abdominal organs, also called visceral fat, contributes to major causes of death and disability, including heart attacks, strokes, high blood pressure, cancer, fatty liver disease and diabetes.
Semaglutide, already approved by the U.S. FDA at the lower dose of 1 mg weekly as a treatment for type 2 diabetes, is a synthetic version of the naturally occurring hormone glucagon-like peptide 1 (GLP1).
It acts on appetite centers in the brain and in the gut, and produces feelings of fullness.
In the study, the team tested 1,961 adults with a body mass index (BMI) of 27 or higher with at least one weight-related health condition, or a BMI of 30 or higher, without diabetes.
A person is classified as overweight if their BMI is 25 to 29.9, and the range for obesity is a BMI of 30 or more.
The participants were assigned to inject themselves once weekly for 68 weeks with either 2.4 milligrams of semaglutide or a placebo.
The team found treatment with semaglutide improved body composition by reducing excess body fat, including abdominal fat, and increasing the proportion of lean body mass, or the amount of weight someone carries that is not body fat.
Patients who injected semaglutide lost close to 15% of their body weight, on average, compared with 2.4% among patients receiving the placebo.
The more bodyweight a participant lost, the greater the improvement in body composition.
More than one-third of participants receiving semaglutide lost more than 20% of their weight. Many patients experienced improvements in risk factors for heart disease, blood sugar levels and quality of life.
If you care about obesity, please read studies about this cancer-fighting compound could fight obesity and diabetes, too and findings of extract from this tree seed may help treat obesity and diabetes.
For more information about obesity and weight loss, please see recent studies about these painkillers may harm your heart and kidneys, causing obesity and sleep disorder and results showing that coffee may be the secret weapon to beat obesity.
Copyright © 2021 Knowridge Science Report. All rights reserved.
